KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Change in Accured Expenses (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Change in Accured Expenses data on record, last reported at -$24.7 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 110.95% year-over-year to -$24.7 million; the TTM value through Dec 2025 reached $736.8 million, changed 0.23%, while the annual FY2025 figure was $736.8 million, 0.23% changed from the prior year.
  • Change in Accured Expenses reached -$24.7 million in Q4 2025 per REGN's latest filing, down from $759.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $759.2 million in Q3 2025 and bottomed at -$250.4 million in Q1 2022.
  • Average Change in Accured Expenses over 5 years is $111.6 million, with a median of $110.5 million recorded in 2024.
  • Peak YoY movement for Change in Accured Expenses: crashed 621.61% in 2022, then soared 460.95% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at -$34.7 million in 2021, then soared by 1101.73% to $347.6 million in 2022, then crashed by 139.9% to -$138.7 million in 2023, then surged by 262.65% to $225.6 million in 2024, then crashed by 110.95% to -$24.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$24.7 million in Q4 2025, $759.2 million in Q3 2025, and $216.4 million in Q2 2025.